Skip to main content
Premium Trial:

Request an Annual Quote

A Standard Approach, But Custom Output

Over at Adaptive Complexity, Michael White blogs about what many perceive as a major goal of synthetic biology: that is, establishing a set of standard biochemical parts that can be used to build systems. "I'm skeptical that any single standardized biological device will hold up well under very different cellular contexts, without a lot of trial-and error modifications," he writes. "Instead of one-size-fits-all parts that probably won't work in many contexts, let's have standardized part-making kits."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.